On Friday, AstraZeneca Plc (NASDAQ:AZN) released positive topline data from Phase 3 OBERON and TITANIA trials of tozorakimab in patients with chronic obstructive pulmonary disease (COPD), also known as smoker’s lung disease.

Positive COPD Data

Tozorakimab is a monoclonal antibody targeting interleukin-33 (IL-33), which inhibits the signalling of the reduced and oxidised forms of IL-33, offering the potential to both reduce inflammation and disrupt the cycle of mucus dysfunction that contributes to COPD worsening.

The data showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo.

Primary Endpoint Achieved Across Broad Patient Groups

The trials met the primary endpoint in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil counts and all stages of ...